Distances to access buprenorphine/naloxone treatment in a rural state.

Authors

Jayme Steig, Isaiah Ratz, Jenna Gorder, Landon Woinarowicz

Published in

Journal of the American Pharmacists Association : JAPhA. Pages 103572. Oct 28, 2026. Epub Oct 28, 2026.

Abstract

Access to buprenorphine/naloxone (BUP/NX) treatment is essential for managing opioid use disorder (OUD), yet significant barriers persist, particularly in rural areas.
This study aims to evaluate the accessibility of BUP/NX treatment in North Dakota by using Prescription Drug Monitoring Program (PDMP) records to calculate distances between individuals and prescribing providers and dispensing pharmacies for BUP/NX treatment in calendar year 2022.
This retrospective study used PDMP records to calculate distance between the ZIP code location of individuals dispensed buprenorphine/naloxone medications, their prescribing providers, and their dispensing pharmacies. Records were grouped in 3 digit ZIP codes to assess geographic and urban-rural variation within North Dakota. Wilcoxon signed-rank tests compared individual-to-pharmacy and individual-to-provider distances within each 3-digit ZIP code region, with a sign test performed as a secondary statewide analysis.
Across North Dakota, the mean individual-to-provider distance was more than twice the individual-to-pharmacy distance, averaging 54.2 miles versus 23.9 miles, respectively. The magnitude of this difference varied across 3-digit ZIP code regions. Wilcoxon signed-rank tests demonstrated significant differences between individual-to-provider and individual-to-pharmacy distances in all regions (p<0.001 for all regions except 586, p=0.017). Completely rural regions had greater individual-to-provider, individual-to-pharmacy, and provider-to-pharmacy distances than regions containing a metropolitan area (all p<0.001).
These findings demonstrate both the potential and the limitations of North Dakota's treatment infrastructure. Pharmacies provide a strong base of access, but prescriber shortages persist as a significant barrier to equitable care. PDMP data offer a valuable surveillance tool to monitor these trends and guide region-specific interventions aimed at reducing opioid-related disparities.

PMID:
42951250
Bibliographic data and abstract were imported from PubMed on 29 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.